Publication:
Biologic agents in psoriasis

Placeholder

Organizational Units

Authors

Başkan, Emel Bülbül

Authors

Advisor

Language

Publisher:

Vakıf Gureba Eğitim ve Araştırma Hastanesi Kliniği

Journal Title

Journal ISSN

Volume Title

Abstract

Psoriasis is a chronic, inflammatory disease affecting 1-3% of population. Advances in the pathogenesis of psoriasis and biotechnology have led to the development of targeted therapy named biologic agents. in this review, general information on biologic drugs are presented and literature on four biologic agents available in our country for moderate to severe plaque psoriasis has been summarized. Mechanisms of action, indications and dosage, results of clinical studies and safety profiles of each biologic agent are discussed.

Description

Source:

Keywords:

Keywords

Dermatology, Adalimumab, Biologics, Efalizumab, Etanercept, Infliximab, Psoriasis, Chronic plaque psoriasis, Randomized controlled-trial, Patient-reported outcomes, Long-term, treatment, Phase-III, Double-blind, Efalizumab therapy, Rheumatoid-arthritis, Open-label, Infliximab monotherapy

Citation

Başkan, E. B. (2008). "Biologic agents in psoriasis". Turkderm Deri Hastaliklari ve Frengi Arsivi, 40(Supplement 2), 42-50

Endorsement

Review

Supplemented By

Referenced By

1

Views

0

Downloads